TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$275 Million

Kymera Therapeutics, Inc.

Follow-on Offering

Bookrunner, January 2024

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (“Kymera” or the “Company”) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation (TPD) platform allows the Company to discover highly selective small molecule protein degraders with activity against disease causing proteins throughout the body. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics.